Featured Content

The Gold Rush and Monopoly Land grab in eClinical growth

Wednesday, November 1, 2017

In 2015, the global eClinical software market was forecasted to reach $6.8 billion by 2020. Recent research now doubles that estimate by 2024. The global increase in clinical trials is driving this growth, as the industry evolves from its slow paper-based methods and standalone spreadsheets toward automated, cloud-based systems to confront the oft-mentioned costs of drug development.

[Read More]

Increasing participation in clinical trials among underrepresented populations

Wednesday, November 1, 2017

Reaching under-represented populations has been a challenge to clinical trial patient recruitment for years. Sponsors, CROs, recruitment vendors and sites have all struggled to find the right approach for reaching these diverse groups. While these target audiences are not necessarily small, they each have unique characteristics that can make it more difficult to engage them in the clinical trial process.

[Read More]

Pay clinical trial patients back with lay language summaries

Wednesday, November 1, 2017

How do you thank someone for taking part in a clinical trial? Evidence is mounting that an effective way to thank study volunteers is to provide them with a plain-language summary of the trial results. Plain, or lay-language summaries, distill the findings of the clinical trial into a brief summary that is understandable to the general public. Various studies show that most participants want the results of their trial but they are not consistently receiving them. In addition to the results, plain-language summaries provide participants with a greater general understanding of the trial. Providing these summaries is shown to improve the overall satisfaction with trials and a higher likelihood for future clinical trial participation.

[Read More]

The evolution of mobile technology use in clinical trials

Wednesday, October 18, 2017

William Osler, a founder of Johns Hopkins University, was a clinician ahead of his time. He was one of the first doctors to bring medical students out of the lecture hall and to the patient’s bedside — a revolutionary format change in its day. His 1892 book, The Principles and Practice of Medicine, was labeled as an “imaginative new curriculum” that prevailed for 50 years.1 Osler once said, “The good physician treats the disease; the great physician treats the patient who has the disease.”

[Read More]

Smart video conferencing a CNS diagnostic tool for CROs

Monday, October 2, 2017

For the past 20 years, we have watched cell phones morph into smart devices that do just about any function you can name. In this same converging trend, video conferencing systems now include “Smart” technologies enabling a multitude of functions to be performed beyond the legacy video conference function. Today, a CNS diagnostic tool has been created specifically for CRO usage using video conferencing.

[Read More]

New evidence extends validation for quality review

Monday, October 2, 2017

The Good ReseArch for Comparative Effectiveness (GRACE) checklist is a simple 11-item tool that considers the study purpose and provides questions to guide high-level evaluation of methods, data quality and analytics for use in health technology assessments of effectiveness and safety studies. It provides a scoring tool to help evaluate studies in the context of the study goal, and can be used by sophisticated and less experienced users.

[Read More]

Integrated delivery of CRO services

Friday, September 1, 2017

Unified delivery of a broad range of services by a CRO within a single clinical trial can be difficult to do as each role within a CRO—be it a Clinical, Data or Laboratory Project Manager, is primarily focused on delivery of their own aspects of the trial.

[Read More]

Planning for proactive pharmacovigilance

Friday, September 1, 2017

The role of pharmacovigilance is becoming increasingly prominent, with scope to inform product strategy and health economics. A recent industry debate hosted by ProductLife Group saw some interesting tips for clinical operations.

[Read More]

The CenterWatch Monthly Industry Close-Up, September 2017

Friday, September 1, 2017

In 2017, 13% of cancer diagnosed in adults will be rare cancers. Of those, prostate cancer represents 9.6% in the U.S. Prostate cancer is the second most common cancer and the second leading cause of cancer-related death in men in the U.S. According to the National Center for Health Statistics, approximately $11.9 billion is spent each year in the U.S. on prostate cancer treatment.

[Read More]